Latest Biotech News

Page 24 of 27
PYC Therapeutics is set to raise up to $146 million through a pro-rata entitlement offer, aiming to accelerate its RNA-based drug candidates targeting major unmet medical needs. Major shareholder support and underwriting commitments underpin the capital raise.
Ada Torres
Ada Torres
17 Feb 2025
Neurizon Therapeutics received FDA guidance on its IND application for NUZ-001, with a single request for additional animal exposure data but no safety concerns flagged. The company is actively addressing the FDA’s request while evaluating impacts on its ALS trial timeline.
Ada Torres
Ada Torres
17 Feb 2025
Avecho Biotechnology has responded to an ASX price query, confirming no undisclosed information exists to explain recent trading spikes, while highlighting market speculation linked to its Phase III CBD insomnia trial.
Ada Torres
Ada Torres
14 Feb 2025
Recce Pharmaceuticals has temporarily paused trading of its securities, signaling a potentially significant development pending further disclosure.
Victor Sage
Victor Sage
13 Feb 2025
Alterity Therapeutics has raised A$40 million through a two-tranche placement to advance its lead compound ATH434 for neurodegenerative diseases, including Multiple System Atrophy and Parkinson's disease.
Ada Torres
Ada Torres
10 Feb 2025
Arovella Therapeutics has requested a voluntary suspension of its ASX-listed securities pending a material announcement on a capital raising, expected by 17 February 2025.
Ada Torres
Ada Torres
10 Feb 2025
BTC Health has transformed its decade-long license agreement with Arna Pharma into an indefinite partnership, gaining royalties from Singapore and Malaysia sales and first rights to new pharmaceutical products in Australia and New Zealand.
Ada Torres
Ada Torres
10 Feb 2025
Nyrada has secured ethics approval to begin its first-in-human Phase Ia trial of NYR-BI03, a promising neuro- and cardioprotective drug candidate. Recruitment starts soon, with dosing expected by March and results due in Q3 2025.
Ada Torres
Ada Torres
7 Feb 2025
Invex Therapeutics reports a significant reduction in net loss for H1 FY2025 alongside promising pre-clinical data for Exenatide in Alzheimer’s Disease models.
Victor Sage
Victor Sage
7 Feb 2025
AdAlta Limited is accelerating its 'East to West' cellular immunotherapy strategy, aiming to bridge Asian innovation with Western clinical development and manufacturing to target solid cancers. The company plans to secure three assets by the end of 2025 and initiate clinical trials, positioning itself as a leader in this emerging market.
Ada Torres
Ada Torres
7 Feb 2025
AdAlta has fast-tracked its cellular immunotherapy growth by signing two new term sheets for clinical-stage CAR-T products from Asia, pivoting to focus on in-licensing and clinical trials while winding down internal R&D on its antifibrotic drug AD-214.
Ada Torres
Ada Torres
6 Feb 2025
Noxopharm has successfully completed key in vitro safety tests for its SOF-SKN™ lupus drug, paving the way for the upcoming HERACLES Phase 1 clinical trial.
Ada Torres
Ada Torres
4 Feb 2025